AGENUS INC Interest Income (Expense), Nonoperating, Net
AGENUS INC (AGEN) reported Interest Income (Expense), Nonoperating, Net of -$15.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-07
- AGENUS INC interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was -$15.24M.
- AGENUS INC interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was -$14.67M.
- AGENUS INC interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was -$16.02M.
- AGENUS INC interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was -$13.17M.
- AGENUS INC interest income (expense), nonoperating, net for fiscal 2025 was -$55.27M.
- AGENUS INC interest income (expense), nonoperating, net for fiscal 2024 was -$117.63M.
- AGENUS INC interest income (expense), nonoperating, net for fiscal 2023 was -$97.92M.
- AGENUS INC interest income (expense), nonoperating, net for fiscal 2022 was -$61.86M.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 3 month as first filed | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 6 month as first filed | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 9 month as first filed | Interest Income (Expense), Nonoperating, Net 12 month | Interest Income (Expense), Nonoperating, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$15.24M 10-Q · filed 2026-08-07 | -$29.91M 10-Q · filed 2026-08-07 | -$45.93M derived: sum of 3 quarters · filed 2026-08-07 | -$59.10M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | -$14.67M 10-Q · filed 2026-05-11 | -$30.69M derived: sum of 2 quarters · filed 2026-05-11 | -$43.86M derived: sum of 3 quarters · filed 2026-05-11 | -$57.15M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | -$16.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$29.19M derived: sum of 2 quarters · filed 2026-03-16 | -$42.48M derived: sum of 3 quarters · filed 2026-08-07 | -$55.27M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | -$13.17M 10-Q · filed 2025-11-10 | -$26.46M derived: sum of 2 quarters · filed 2026-08-07 | -$39.25M 10-Q · filed 2025-11-10 | -$59.94M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | -$13.29M 10-Q · filed 2026-08-07 | -$26.08M 10-Q · filed 2026-08-07 | -$46.77M derived: sum of 3 quarters · filed 2026-08-07 | -$82.50M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | -$12.79M 10-Q · filed 2026-05-11 | -$33.48M derived: sum of 2 quarters · filed 2026-05-11 | -$69.21M derived: sum of 3 quarters · filed 2026-05-11 | -$100.95M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$20.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$56.41M derived: sum of 2 quarters · filed 2026-03-16 | -$88.16M derived: sum of 3 quarters · filed 2026-03-16 | -$117.63M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | -$35.73M 10-Q · filed 2025-11-10 | -$67.47M derived: sum of 2 quarters · filed 2025-11-10 | -$96.94M 10-Q · filed 2025-11-10 | -$141.12M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2024-06-30 | -$31.75M 10-Q · filed 2025-08-11 | -$61.21M 10-Q · filed 2025-08-11 | -$105.39M derived: sum of 3 quarters · filed 2026-03-16 | -$124.02M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2024-03-31 | -$29.47M 10-Q · filed 2025-05-12 | -$73.65M derived: sum of 2 quarters · filed 2026-03-16 | -$92.28M derived: sum of 3 quarters · filed 2026-03-16 | -$110.80M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2023-12-31 | -$44.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$62.81M derived: sum of 2 quarters · filed 2026-03-16 | -$81.33M derived: sum of 3 quarters · filed 2026-03-16 | -$97.92M 10-K · filed 2026-03-16 | ||||
| 2023-09-30 | -$18.63M 10-Q · filed 2024-11-12 | -$37.15M derived: sum of 2 quarters · filed 2024-11-12 | -$53.74M 10-Q · filed 2024-11-12 | -$71.07M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-06-30 | -$18.52M 10-Q · filed 2024-08-08 | -$35.11M 10-Q · filed 2024-08-08 | -$52.44M derived: sum of 3 quarters · filed 2025-03-17 | -$68.04M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-03-31 | -$16.59M 10-Q · filed 2024-05-07 | -$33.92M derived: sum of 2 quarters · filed 2025-03-17 | -$49.52M derived: sum of 3 quarters · filed 2025-03-17 | -$63.26M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2022-12-31 | -$17.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$32.93M derived: sum of 2 quarters · filed 2025-03-17 | -$46.66M derived: sum of 3 quarters · filed 2025-03-17 | -$61.86M 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | -$15.61M 10-Q · filed 2023-11-09 | -$29.34M derived: sum of 2 quarters · filed 2023-11-09 | -$44.54M 10-Q · filed 2023-11-09 | -$61.11M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-06-30 | -$13.73M 10-Q · filed 2023-08-08 | -$28.93M 10-Q · filed 2023-08-08 | -$45.50M derived: sum of 3 quarters · filed 2024-03-14 | -$62.08M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-03-31 | -$15.20M 10-Q · filed 2023-05-09 | -$31.77M derived: sum of 2 quarters · filed 2024-03-14 | -$48.35M derived: sum of 3 quarters · filed 2024-03-14 | -$65.03M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | -$16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$33.15M derived: sum of 2 quarters · filed 2024-03-14 | -$49.83M derived: sum of 3 quarters · filed 2024-03-14 | -$65.72M 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | -$16.58M 10-Q · filed 2022-11-08 | -$33.26M derived: sum of 2 quarters · filed 2022-11-08 | -$49.15M 10-Q · filed 2022-11-08 | -$65.35M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-06-30 | -$16.68M 10-Q · filed 2022-08-09 | -$32.57M 10-Q · filed 2022-08-09 | -$48.77M derived: sum of 3 quarters · filed 2023-03-16 | -$64.98M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-03-31 | -$15.89M 10-Q · filed 2022-05-10 | -$32.09M derived: sum of 2 quarters · filed 2023-03-16 | -$48.30M derived: sum of 3 quarters · filed 2023-03-16 | -$62.93M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2020-12-31 | -$16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$32.41M derived: sum of 2 quarters · filed 2023-03-16 | -$47.04M derived: sum of 3 quarters · filed 2023-03-16 | -$61.08M 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | -$16.21M 10-Q · filed 2021-11-09 | -$30.84M derived: sum of 2 quarters · filed 2021-11-09 | -$44.87M 10-Q · filed 2021-11-09 | -$56.73M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | -$14.63M 10-Q · filed 2021-08-09 | -$28.66M 10-Q · filed 2021-08-09 | -$40.52M derived: sum of 3 quarters · filed 2022-03-01 | -$51.18M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | -$14.04M 10-Q · filed 2021-05-07 | -$25.89M derived: sum of 2 quarters · filed 2022-03-01 | -$36.55M derived: sum of 3 quarters · filed 2022-03-01 | -$46.34M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | -$11.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$22.51M derived: sum of 2 quarters · filed 2022-03-01 | -$32.31M derived: sum of 3 quarters · filed 2022-03-01 | -$41.45M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | -$10.66M 10-Q · filed 2020-11-09 | -$20.45M derived: sum of 2 quarters · filed 2020-11-09 | -$29.60M 10-Q · filed 2020-11-09 | -$38.33M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-06-30 | -$9.80M 10-Q · filed 2020-08-10 | -$18.94M 10-Q · filed 2020-08-10 | -$27.67M derived: sum of 3 quarters · filed 2021-03-16 | -$35.21M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-03-31 | -$9.14M 10-Q · filed 2020-05-11 | -$17.87M derived: sum of 2 quarters · filed 2021-03-16 | -$25.41M derived: sum of 3 quarters · filed 2021-03-16 | -$31.64M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2018-12-31 | -$8.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$16.27M derived: sum of 2 quarters · filed 2021-03-16 | -$22.49M derived: sum of 3 quarters · filed 2021-03-16 | -$25.27M 10-K · filed 2021-03-16 | -$25.27M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | -$7.54M 10-Q · filed 2019-11-07 | -$7.54M 10-Q · filed 2018-11-07 | -$13.76M derived: sum of 2 quarters · filed 2019-11-07 | -$16.54M 10-Q · filed 2019-11-07 | -$16.54M 10-Q · filed 2018-11-07 | -$21.65M derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2018-06-30 | -$6.22M 10-Q · filed 2019-08-09 | -$6.22M 10-Q · filed 2018-08-09 | -$9.01M 10-Q · filed 2019-08-09 | -$9.00M 10-Q · filed 2018-08-09 | -$14.11M derived: sum of 3 quarters · filed 2020-03-16 | -$18.81M derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2018-03-31 | -$2.78M 10-Q · filed 2019-05-10 | -$2.78M 10-Q · filed 2018-05-10 | -$7.88M derived: sum of 2 quarters · filed 2020-03-16 | -$12.59M derived: sum of 3 quarters · filed 2020-03-16 | -$17.06M derived: sum of 4 quarters · filed 2020-03-16 | |||
| 2017-12-31 | -$5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$9.81M derived: sum of 2 quarters · filed 2020-03-16 | -$14.28M derived: sum of 3 quarters · filed 2020-03-16 | -$18.87M 10-K · filed 2020-03-16 | -$18.87M 10-K · filed 2018-03-16 | |||
| 2017-09-30 | -$4.70M 10-Q · filed 2018-11-07 | -$9.18M derived: sum of 2 quarters · filed 2018-11-07 | -$13.77M 10-Q · filed 2018-11-07 | -$18.34M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-06-30 | -$4.47M 10-Q · filed 2018-08-09 | -$9.06M 10-Q · filed 2018-08-09 | -$13.63M derived: sum of 3 quarters · filed 2019-03-18 | -$18.04M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | -$4.59M 10-Q · filed 2018-05-10 | -$9.16M derived: sum of 2 quarters · filed 2019-03-18 | -$13.57M derived: sum of 3 quarters · filed 2019-03-18 | -$17.77M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | -$4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$8.98M derived: sum of 2 quarters · filed 2019-03-18 | -$13.18M derived: sum of 3 quarters · filed 2019-03-18 | -$17.32M 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | -$4.41M 10-Q · filed 2017-11-07 | -$8.61M derived: sum of 2 quarters · filed 2017-11-07 | -$12.75M 10-Q · filed 2017-11-07 | -$16.98M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2016-06-30 | -$4.20M 10-Q · filed 2017-08-07 | -$8.34M 10-Q · filed 2017-08-07 | -$12.57M derived: sum of 3 quarters · filed 2018-03-16 | -$13.97M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2016-03-31 | -$4.13M 10-Q · filed 2017-05-04 | -$8.37M derived: sum of 2 quarters · filed 2018-03-16 | -$9.77M derived: sum of 3 quarters · filed 2018-03-16 | -$10.33M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2015-12-31 | -$4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$5.64M derived: sum of 2 quarters · filed 2018-03-16 | -$6.20M derived: sum of 3 quarters · filed 2018-03-16 | -$6.60M 10-K · filed 2018-03-16 | ||||
| 2015-09-30 | -$1.40M 10-Q · filed 2016-11-09 | -$1.97M derived: sum of 2 quarters · filed 2016-11-09 | -$2.36M 10-Q · filed 2016-11-09 | -$2.66M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | -$565.52K 10-Q · filed 2016-08-04 | -$962.38K 10-Q · filed 2016-08-04 | -$1.26M derived: sum of 3 quarters · filed 2017-03-16 | -$1.57M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | -$396.86K 10-Q · filed 2016-05-09 | -$696.47K derived: sum of 2 quarters · filed 2017-03-16 | -$1.01M derived: sum of 3 quarters · filed 2017-03-16 | |||||
| 2014-12-31 | -$299.61K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$609.69K derived: sum of 2 quarters · filed 2017-03-16 | -$1.26M 10-K · filed 2017-03-16 | |||||
| 2014-09-30 | -$310.08K 10-Q · filed 2015-11-04 | -$962.01K 10-Q · filed 2015-11-04 | ||||||
| 2013-12-31 | -$2.42M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |